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BACKGROUND: Quercetin is a flavonoid naturally present in food and beverages belonging to the large class of phytochemicals with
potential anti-cancer properties. Here, we investigated the ability of quercetin to sensitise primary cells from chronic lymphocytic
leukaemia (CLL) to death receptor (DR) agonists, recombinant TNF-related-apoptosis-inducing ligand (rTRAIL) and anti-CD95, and
to fludarabine, a widely used chemotherapeutic drug against CLL.
METHODS: Peripheral white blood cells were isolated from patients and incubated with medium containing 50 ng ml anti-CD95 agonist
antibody; 10 ng ml recombinant TRAIL; 10–25 mM quercetin and 3.5–14 mM fludarabine. Neutral Red assay was used to measure cell
viability, where as apoptosis was assessed by determining caspase-3 activity, exposure to Annexin V and PARP fragmentation.
RESULTS: Quercetin significantly enhanced anti-CD95- and rTRAIL-induced cell death as shown by decreased cell viability, increased
caspase-3 and -9 activities, and positivity to Annexin V. In addition, association of quercetin with fludarabine increases the apoptotic
response in CLL cells of about two-fold compared with quercetin monotreatment.
CONCLUSION: This work shows that resistance to DR- and fludarabine-induced cell death in leukaemic cells isolated from CLL patients
can be ameliorated or bypassed by the combined treatment with quercetin. Considering the low toxicity of the molecule, our study
results are in favour of a potential use of quercetin in adjuvant chemotherapy in combination with other drugs.
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Chronic lymphocytic leukaemia (CLL) is the most frequent form of
leukaemia in adult population (22–30% of all leukaemia cases) with
an incidence projected to be between 1 and 5.5 per 100000 people in
the Western world (Yee and O’Brien, 2006). Approximately, 50% of
CLL patients remain asymptomatic and are diagnosed by unrelated
lymphocytosis. Treatment depends on the clinical staging (Rai or
Binet classification) and, originally, included conventional therapy
based on alkylating/anthracycline agents. The introduction in therapy
of fludarabine, a purine analogue, substantially improved overall and
complete responses when used both as monotherapy (Johnson et al,
1996) and in association with alkylating agents (Eichhorst et al, 2006).
Recently, treatment with humanised monoclonal antibodies, such as
rituximab and alemtuzumab has been used as induction therapy and
in patients with refractory CLL (Yee and O’Brien, 2006). In these
patients, modest improvement has been achieved with rituximab or
combined chemotherapy. Despite this, a significant percentage of
untreated patients (up to 37%) do not respond to fludarabine
treatment, or become refractory to this regime of treatment (up to
76%). Moreover, a variable number of these subjects occasionally
incur in severe side effects, such as neutropenia, suppression of
helper T cells, acute tumour lysis syndrome, autoimmune haemolysis,
and neurotoxicity (Yee and O’Brien, 2006).
Cell death evasion and progressive accumulation of B cells are
the major relevant events in CLL pathogenesis, so targeting
apoptotic pathways triggered by CD95 (Fas/Apo-1) and TNF-
related-apoptosis-inducing ligand (TRAIL)/Apo-2 death receptors
(DRs) has been suggested as novel therapeutic approaches to treat
this leukaemia (Pleyer et al, 2009). CD95 and TRAIL belong to
the TNF receptor superfamily regulating the extrinsic apoptotic
pathways after the interaction with their cognate ligand. Both
CD95 and TRAIL are potential candidates to target apoptosis in
malignant cells (Debatin and Krammer, 2004; Papenfuss et al,
2008; Russo et al, 2010). However, one drawback of this
therapeutic strategy is the resistance to DR-induced cell death in
B-CLL patients (MacFarlane et al, 2002, 2005).
In this context, a plethora of naturally occurring molecules with
chemopreventive properties have been suggested as potential
candidates in adjuvant chemotherapy when associated with other
drugs (Aggarwal and Shishodia, 2006; Mansour et al, 2007; Russo,
2007; Fimognari et al, 2008). In this article, we show that quercetin
(3,30,40,5,7-pentahydroxyflavone), a naturally occurring flavonoid
widely present in fruits and beverages (Lamson and Brignall, 2000;
Day et al, 2003) and possessing anti-cancer activity (Russo, 2007;
Bischoff, 2008; Murakami et al, 2008), is able to sensitise leukaemic
cells isolated from CLL patients when associated with recombinant
TRAIL (rTRAIL) or anti-CD95 agonistic antibody. We also showed
that quercetin potentiates the effect of fludarabine on resistant
B-CLL cells. The rationale for investigating the sensitising effect of
quercetin on CLL derives from previous works on leukaemic cell
lines showing the apoptogenic activity of the molecule on cell lines
resistant to DR-induced cell death (Russo et al, 1999, 2003, 2007). Revised 19 May 2010; accepted 17 June 2010; published online 20 July 2010
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cancer and apoptogenic effects of quercetin at relatively low
concentrations (10-25 mM) in primary tumour cells.
MATERIALS AND METHODS
Reagents
Roswell Park Medium Institute (RPMI) medium, L-glutamine
200mM, penicillin 5000IUml
 1/streptomycin 5000mgml
 1 and
phosphate-buffered saline (PBS) tablets were purchased from
Invitrogen (S Giuliano Milanese, Milan, Italy). Neutral red 0.33%
solution, propidium iodide, Trypan blue solution (0.4%), querce-
tin, and dimethyl sulfoxide (DMSO) were from Sigma-Aldrich
(Milan, Italy). Annexin V-FITC, rTRAIL (super killer TRAIL),
caspase-3 and -9 substrates were from Enzo Life Sciences
(AG Lausen, Switzerland). Anti-CD95 (clone CH-11) was from
Immunotech (Marseille, France). Fludarabine phosphate was gifted
by Onco-Haematology Division, SG Moscati Hospital (Avellino,
Italy), participating in this study.
Cell isolation and viability tests
Mononuclear cells (leukaemic cells 490%) were isolated from
peripheral blood of 47 patients with B-CLL. All clinical samples
were obtained after informed consent. Following density-gradient
centrifugation (Ficoll-Paque Plus; GE Healthcare, Milan, Italy),
cells were washed three times in PBS, counted with Trypan blue
dye to assess their viability (cell viability 495%), and were
immediately cultured in RPMI supplemented with 1% penicillin/
streptomycin, 2mML -glutamine and 10% autologous serum
(Bomstein et al, 2003), at 371C in a humidified atmosphere
containing 5% CO2. For neutral red assay (Fautz et al, 1991), we
cultured the cells at density of 1 10
6 per ml in 48 multi-well
plates and incubated (24–48h) in a medium containing 0.1%
DMSO, 10–25mM quercetin solubilised in 0.1% DMSO, rTRAIL
(10ngml
 1), anti-CD95 (50ngml
 1), or fludarabine dissolved in
PBS (3.5–14mM final concentration). Cell viability assay was
performed as described (Russo et al, 2003).
Apoptosis assays
Phosphatidylserine exposure was measured using the binding of
fluorescein-isothiocyanate-labelled (FITC) Annexin V to phospha-
tidylserine, as per the manufacturer’s protocol (Enzo Life Sciences).
Briefly, cells (2 10
6 per ml) were washed in PBS and suspended in
binding buffer (10mM HEPES (pH 7.4); 140mM NaCl; 2.5mM
CaCl2). Annexin V FITC (5ml) and propidium iodide (10ml) were
added to the cells for 10–15min in the dark at room temperature
and analysed with flow cytometer (FACSCalibur; Becton Dickinson,
Mountain View, CA, USA) equipped with argon laser (488nm) and
filtered at 530 and 585nm for FITC and phycoerythrin respectively.
Low fluorescence debris and necrotic cells, permeable to propidium
iodide, were gated out before to analysis and 10–20 000 events were
collected. Data were analysed using CellQuest software (Becton
Dickinson). This assay was also used to measure spontaneous
apoptosis in freshly isolated B-CLL cells.
For caspase-3 and -9 enzymatic activities, we incubated cells
(2 10
6 per ml) for 12–16h as described above for the cell
viability test. At the end of incubation, cells were washed twice
in PBS and suspended in lysis buffer (10mM HEPES (pH 7.4),
2m M ethylenediaminetetraacetic acid, 0.1% 3-((3-cholamidopro-
pyl)dimethylammonio)-1-propanesulfonate, 5mM dithiothreitol,
1m M phenylmethylsulfonylfluoride, 10mgml
 1 pepstatin-A,
10mgml
 1 apronitin, 20mgml
 1 leupeptin). Following measure-
ment of protein concentration (Bradford, 1976), cell extracts were
added with reaction buffer and the respective conjugated amino-
4-trifluoromethyl coumarin (AFC) substrates, for example,
benzyloxycarbonyl-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-AFC(Z-
DEVD-AFC)for caspase-3 and LEHD-AFC for caspase-9 (carbo-
benzoxy-Asp-Glu-Val-Asp and Leu-Glu-Hys-Asp-AFC) before in-
cubation at 371C for 30min. Upon proteolytic cleavage of the
substrates by the different caspases, the free fluorochrome AFC
was detected by a spectrofluorometer multiplate reader (FL-500;
Bio-Tek Instruments, Milan, Italy) with excitation and emission
setting of 395±20 and 530±20nm respectively. To quantify
enzymatic activities, we determined an AFC standard curve.
Caspase-specific activities were calculated as nmol of AFC
produced per min per mg proteins at 371C at saturating substrate
concentrations (50mM) (Russo et al, 2003). Fold increase in
caspase-3 and -9 activities was determined by direct comparison
with the level of DMSO-treated cells.
Immunoblot
Cleavage of poly(ADP-ribose) polymerase (PARP) in B-CLL cells
was revealed by immunoblotting using anti-PARP monoclonal
antibody (Santa Cruz Biotechnology, Heidelberg, Germany) as
described (Russo et al, 2007). B-CLL cells (2 10
6 per ml) were
suspended in lysis buffer containing 150mM NaCl, 50mM Tris-HCl
(pH 7.4), 5mM ethylenediaminetetraacetic acid, 1% NP-40,
0.5mM dithiothreitol, 1mM Na3VO4,4 0 m M NaF, 1mM Na4P2O7,
7.4mgml
 1 4-p-nitrophenyl phosphate, 10% glycerol, 100mgml
 1
phenylmethylsulfonyl fluoride and a cocktail of inhibitors
‘complete’ by Roche Applied Science (Monza, Milan, Italy).
Total protein lysates (20–25mg) were loaded on a 12% pre-cast
gel (CRITERION XT; Bio-Rad Laboratories, Segrate, Milan, Italy)
and blotted onto polyvinylidene difluoride (PVDF), hybond-P
membrane (GE Healthcare). The membrane blot was rinsed with
T-TBS (0.1% Tween 20, 25mM Tris, 137mM NaCl, 2.69mM KCl (pH
8)) and blocked by 5% (w/v) non-fat dry milk in T-TBS for 1h at
room temperature. Subsequently, the membrane was incubated for
16h at 41C with anti-PARP antibody and finally incubated with
anti-mouse horseradish-peroxidase-linked secondary antibody
(GE Healthcare). The immunoblots were developed using Western
Lightening Chemiluminescence Reagent Plus (PerkinElmer;
Monza, Milan, Italy).
RESULTS
We first showed that quercetin enhances DR-induced cell death in
leukaemic cells resistant to apoptotic stimuli (Russo et al, 1999,
2007); subsequently, others confirmed our original observation on
cell lines of different origin (Psahoulia et al, 2007; Kim et al,
2008a,b; Siegelin et al, 2009). However, to date, the pro-apoptotic
effects of quercetin have not been investigated in cells isolated
from primary tumours. The rationale of this work was to show if
the sensitising effect of quercetin towards DR-induced cell death
was confirmed in B cells isolated from CLL patients. To this aim,
we isolated mononuclear cells (leukaemic cells 490%) from
peripheral blood of 47 patients with CLL whose clinical features are
reported in Table 1. The diagnosis of CLL was established by
examination of the blood and bone marrow, including immuno-
phenotype of the malignant lymphocytes according to IWCLL
criteria (Hallek et al, 2008). These patients were either untreated or
had not received treatment during the previous 6 months. The
median age at diagnosis was 62 years (range 32–80) with a male to
female ratio of 1:1. At diagnosis the distribution of Rai stages I, II,
III, and IV was 0, 57, 2, and 41% respectively. Several molecules
that modify B-cell receptor signalling, such as ZAP-70 or CD38, as
well as immunoglobulin variable heavy chain gene mutation status
show important prognostic power in B-CLL at early clinical stage
(Pleyer et al, 2009). Table 1 reports positivity to CD38, which is
associated to both survival and proliferation in B-CLL cells. CD38
expression and signalling capacity are also linked to progression
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sand response to therapy (Damle et al, 1999). However, in this
study, no statistical correlation has been measured between
enhanced CD38 expression and cell death induced by quercetin
treatment (Supplementary Figure S1).
Owing to the well-known heterogeneity of B-CLL cells, a
preliminary screening was performed to determine sensitivity to
quercetin, anti-CD95, and rTRAIL (data not reported). This
analysis allowed us to address two essential points: (1) to confirm
that all B-CLL samples were partially or totally resistant to anti-
CD95 or rTRAIL treatments, accordingly to data reported in the
literature previously (MacFarlane et al, 2002, 2005); (2) to establish
the correct range of quercetin concentrations to avoid cytotoxic
doses of quercetin that could mask the ability of the molecule to
sensitise B-CLL cells to DR-dependent apoptosis. Therefore, in this
arm of the study, we excluded samples extremely sensitive to
quercetin (decrease in cell viability higher than 30%; data not
shown) and focused our analyses on cells resistant to DR-induced
apoptosis (indicated by footenote d in Table 1).
Cell viability assays (Figure 1) indicate that quercetin potentiates
sensitivity to anti-CD95 and rTRAIL treatment with an increase in
death cells of about 1.5- and 1.6-fold respectively, when compared
with quercetin monotreatment. This effect is statistically signifi-
cant, as indicated in Figure 1, and suggests the presence of two
parallel events acting on B-CLL cells, both triggered by quercetin:
(1) sensitisation to DR-induced apoptosis, and (2) apoptotic/
cytotoxic effect of quercetin per se. It is noteworthy that cell
viability assay (neutral red) applied to data presented in Figure 1
measured dead cells, without discriminating between apoptosis
and necrosis. Therefore, to confirm that the combined treatment of
quercetin in association with anti-CD95/rTRAIL triggers apoptotic
pathways in B-CLL cells reported in Figure 1, we assayed canonical
markers of DR-induced apoptosis in selected samples (Table 2).
Reduced cell viability parallels with increased caspase-3 activity
and increased percentage of cells positive to Annexin V, a
canonical marker of apoptotic events. Cases reported in Table 2
have been selected based on several criteria: (1) to show that the
effects of quercetin in enhancing DR-induced cell death in terms
of decrease in cell viability, caspase-3 activation, and Annexin V
positivity are more than additive (arrows), supporting the
apoptogenic sensitising capacity of quercetin (CLL-55, 56, 44,
and 11); (2) to show that a limited percentage of samples (about
10%) isolated from B-CLL patients neither respond to quercetin,
nor to the combined treatment (CLL-42), even if a transient
increase in caspase-3 was detected. Probably, the measured
activation of caspase-3 was not sufficient to exceed the minimal
threshold necessary to trigger apoptosis; (iii) to highlight that in
about 60–70% of CLL samples studied, quercetin per se induces
apoptosis, as indicated by decreased cell viability and increased
caspase-3 activity and Annexin V positivity (CLL-55, 44, and 11).
In the remaining cases, an example is CLL-56, the molecule is
simply cytotoxic or triggers caspase-independent events, as
evidenced by a limited caspase-3 activity and Annexin V positivity.
Table 1 Clinical features of CLL patients
Patient Sex Age Stage (Rai) CD38
+a WBC
b
CLL-69
c F 75 IV 68400
CLL-67
d M 70 II 66200
CLL-66
d M 80 IV 3 63400
CLL-62 F 43 II 2 68000
CLL-61
c,d F 62 II 70000
CLL-60
c,d F 72 II 97 77000
CLL-58
c F 75 II 3 65000
CLL-57
c M 65 II 2 62800
CLL-56
c,d M 68 II 20 72000
CLL-55
c,d M 64 II 1 59000
CLL-53 M 52 II 12000
CLL-52
c F 49 II 80100
CLL-51 M 72 IV 7 60500
CLL-50 F 32 II 8 51500
CLL-49
c M 57 IV 42 50000
CLL-47 M 37 IV 3 66900
CLL-46
c,d F 51 II 2 77000
CLL-45
c,d M 64 II 1 59900
CLL-44
c,d F 62 IV 60 67200
CLL-43
c,d M 75 II 0 57000
CLL-42
c M 78 IV 82200
CLL-41
c,d F 65 IV 2 56600
CLL-40
c,d F 66 IV 98 77500
CLL-39
c,d M 62 IV 33 98000
CLL-38
c F 72 II 6 66500
CLL-35
d F 60 II 91100
CLL-34
c,d F 60 II 74 50000
CLL-33
d F 30 0 16000
CLL-32
c,d M 66 II 0 63000
CLL-30
d M 54 IV 6 46000
CLL-29
c,d M 63 IV 56300
CLL-28
c,d M 48 II 0 89200
CLL-27 M 75 III 1 140000
CLL-26
c,d M 65 II 10 62000
CLL-25
c,d F 71 IV 15 65900
CLL-24
c,d F 60 II 56 82500
CLL-23
d M 56 II 78 57900
CLL-22
c,d F 32 IV 135000
CLL-20 M 62 II 6 85900
CLL-19 F 74 IV 97 105000
CLL-18
d M 62 IV 89 55800
CLL-17 F 76 II 2 65400
CLL-16 M 65 IV 0 49200
CLL-15
c,d F 77 II 92 84100
CLL-14
c,d F 63 II 1 65400
CLL-12 M 59 II 0 80000
CLL-11
c,d F 74 IV 40000
Abbreviations: CLL¼chronic lymphocytic leukaemia; M¼male; F¼female;
WBC¼white blood cell.
aPositivity to CD38. Accordingly to Schroers et al (2005)
a 30% cut-off point was used; that is, the samples were considered CD38 positive if
the antigen was present in 30% or more tumor cells and negative if expression was
present in less than 30% cells.
bno fcells per ml whole blood.
cSamples analysed in
Figure 4.
dSamples analysed in Figure 1.
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Figure 1 Cell viability assay in cells isolated from CLL patients and
treated with quercetin and anti-CD95 or rTRAIL. Concentrations are as
reported in Table 2. Values are presented as mean±s.e. (n¼29) and
significant differences were calculated using the two-tailed paired t-test.
Asterisk (*) indicates significant difference from quercetin (Po0.001) and
rTRAIL (Po0.0001), whereas (#) indicates significant difference from
quercetin (Po0.001) and anti-CD95 (Po0.0001).
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rTRAIL has been also confirmed by the degradation of PARP.
Demonstrative examples are shown in Figure 2. In the case of
sample CLL-67 (panel A), the combined treatment (quercetin
along with rTRAIL) increases PARP degradation compared
with single treatments, whereas in the second case (panel B,
corresponding to CLL-44), the apoptotic effect of quercetin
monotreatment is prevalent, as shown in Table 2 in terms of cell
viability, caspase-3 activation and annexin V exposure.
In selected samples, which showed an enhancing effect of
quercetin associated with DR agonists, we also measured the
activation of caspase-9. These experiments were carried out to
show the ability of quercetin to trigger the intrinsic apoptotic
pathway, which is characterized by release of mitochondrial
cytochrome c into the cytosol and procaspase-9 processing. In
the cytosol, cytochrome c binds to apoptosis protease activation
factor 1 and the resultant complex recruits caspase-9 leading to its
activation and cleavage of downstream caspases (Kuida, 2000). As
shown in Figure 3, quercetin monotreatment increases caspase-9
activity by 3.5- and 4-fold in CLL-56 and CLL-55 respectively. This
effect was further enhanced in the combined treatments with anti-
CD95 and rTRAIL (Figure 3), confirming data reported in Table 2.
It is interesting to note that increased caspase-9 by quercetin
monotreatment in CLL-56 did not match with a strong activation
of caspase-3 and apoptotic induction (Table 2), which, in turn, was
obtained only in the combined treatments.
In the majority of B-CLL cells investigated, quercetin mono-
treatment induced cell death at concentrations significantly lower
than those showing cytotoxicity on cell lines of leukaemic origin
(Russo et al, 2007; data not shown). On the basis of this
observation, we reasoned that quercetin could also strengthen
the efficacy of drugs widely used in the therapy of CLL, such as
fludarabine (Yee and O’Brien, 2006). To test this possibility, we
treated the samples isolated from B-CLL patients (indicated by
footenote c in Table 1), showing a significant resistance to 3.5–
14mM fludarabine, with quercetin in combination with fludarabine.
It is noteworthy that 3.5mM represents the therapeutic plasma
concentration of fludarabine (Binet, 1993). As reported in Figure 4,
the association between quercetin and fludarabine increases cell
death by approximately two-fold when compared with quercetin
Table 2 Effects of quercetin on anti-CD95- and rTRAIL-induced apoptosis in cells isolated from CLL patients
Patient Treatment Cell viability (%) Caspase-3 (fold) Annexin V (% positivity)
Quercetin 10mM 86.7±0.9 1.4±0.3 3
rTRAIL 10ngml
 1 101.5±0.9 1.4±0.4 3
CLL 56 Anti-CD95 50ngml
 1 97.0±1.5 1.6±0.4 0
rTrial+Quercetin 66.2±2.7 k 5.6±0.4 m 15 m
Anti-CD95+quercetin 77.7±0.69 k 7.0±0.3 m 10 m
Quercetin 10mM 72.1±2.3 3.7±0.25 15
rTRAIL 10ngml
 1 97.2±3.7 0.79±0.01 5
CLL 55 Anti-CD95 50ngml
 1 106.9±5.5 1.39±0.15 1
rTrial+Quercetin 61.5±2.4 k 4.6±0.43 m 21 m
Anti-CD95+Quercetin 66.2±3.5 k 5.5±0.15 m 22 m
Quercetin 25mM 67±2.1 1.9±0.2 22
rTRAIL 10ngml
 1 92.0±2.5 1.4±0.08 8
CLL 44 Anti-CD95 50ngml
 1 95.6±3.5 1.17±0.07 5
rTrial+Quercetin 55.5±3.3 k 4.07±0.07 m 33 m
Anti-CD95+Quercetin 55.6±1.8 k 3.6±0.2 m 35 m
Quercetin 25mM 92±3.2 2.1±0.1 6
rTRAIL 10ngml
 1 114±8.5 2.0±0.06 0
CLL 42 Anti-CD95 50ngml
 1 101.4±2.0 1.3±0.06 3
TRAIL+Quercetin 103.2±3.7 1.9±0.2 6
Anti-CD95+Quercetin 107.3±3.5 2.0±0.06 5
Quercetin 25mM 77.5±3.6 2.1±0.05 20
rTRAIL 10ngml
 1 90.5±8.5 1.2±0.16 7
CLL 11 Anti-CD95 50ngml
 1 95.5±2.0 0.77±0.11 12
rTRAIL+Quercetin 60±2.4 k 4.1±0.44 m 33 m
Anti-CD95+Quercetin 75.5±3.6 k 2.6±0.2 m 30 m
Abbreviations: CLL¼chronic lymphocytic leukaemia; rTRAIL¼recombinant TNF-related-apoptosis-inducing ligand. Arrows indicate that the decrease (k) in cell viability, or the
increase (m) in caspase-3 activity and Annexin V positivity were more than additive with respect to single treatments with quercetin, anti-CD95, or rTRAIL. Percentage of
Annexin V positivity was calculated subtracting basal values ranging between 10 and 30%.
120
CLL-67
C
85
T+Q
CLL-44
120
85
C
TQ
CD+Q T+Q Q CD T
Figure 2 Cleavage of PARP in cells isolated from CLL patients.
Immunoblottings show the proteolytic cleavage of PARP by caspase-3 in
two selected samples isolated from CLL patients (CLL-67 and CLL-44 in
panels A and B respectively). Cells from CLL-44 were treated as indicated
in Table 1, whereas sample CLL-67 was treated with 20mM quercetin
and 10ngml
 1 rTRAIL. C, Q, T, CD indicate DMSO and quercetin, rTRAIL,
anti-CD95 treated cells. Numbers on the left indicate the molecular weight
of uncleaved (120kDa) and cleaved (85kDa) PARP. Images are
representative of one experiment out of two performed for each sample.
Quercetin potentiates apoptosis in CLL
M Russo et al
645
British Journal of Cancer (2010) 103(5), 642–648 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sand by six-fold with respect to fludarabine. Differences were
significant, as indicated in Figure 4. Selected samples listed in
Table 3 show that the pro-apoptotic effects of the combined
treatment are more than additive (arrows) with respect to the three
markers used to assess cell death, suggesting the enhancing
apoptogenic effect of quercetin also in association with fludar-
abine. The pleiotropic effect of quercetin on multiple cellular
targets is exemplified in sample CLL-42, which is resistant to
CD95-, TRAIL- (Table 2), and fludarabine-induced (Table 3)
apoptosis. Quercetin is not able to bypass resistance to DR
agonists, but ameliorates the sensitivity to fludarabine.
DISCUSSION
The development of high selective drugs triggering specific
molecular target is the desirable and ambitious objective in
leukaemia treatment. A suitable example is represented by
the development of the tyrosine kinase inhibitor imatinib that
has revolutionised the treatment of chronic myeloid leukaemia
(Stegmeier et al, 2010). However, in the case of CLL, its
heterogeneous nature and the resistance to conventional treat-
ments developing in the majority of patients hinder the progresses
in therapy. Our study opens new applicative perspectives
supported by the observation that TRAIL receptor is preferentially
expressed on malignant cells and appears a better candidate in
cancer therapy and in B-CLL leukaemias, with respect to the high
liver toxicity of anti-CD95 treatment (Igney and Krammer, 2002;
MacFarlane et al, 2005).
Overall, this work shows that resistance to DR- and fludarabine-
mediated cell death in leukaemic cells isolated from B-CLL patients
can be ameliorated or bypassed by the combined treatment with
quercetin. Similar data have been reported by our group in
leukaemia cell lines resistant to DR-induced apoptosis (Russo et al,
1999, 2007). However, as mentioned above, this work represents, to
the best of our knowledge, the first evidence that quercetin may
potentiate apoptosis in cells isolated from primary tumours.
From data presented in Figures 1–3 and Table 2, we can
hypothesise that in leukaemic cells isolated from B-CLL patients,
the apoptotic response mediated by DRs could be inhibited, or
strongly reduced, by unknown interfering mechanisms functioning
on the extrinsic pathways. Quercetin is able to loosen this block
potentiating DR-induced apoptosis in CLL cells. This implies the
presence of a functional CD95 or TRAIL receptors. Only if this
condition is verified quercetin can free the apoptotic pathways
downstream CD95/TRAIL that are blocked or inhibited by
anti-apoptotic factors. We also suggest that the moderate but
significant enhancing effect of quercetin in inducing apoptosis
when associated with anti-CD95, rTRAIL, and fludarabine (Figures
1 and 4) can be explained evoking the variability of B-CLL cells
and the heterogeneity of the disease.
New combined therapeutic treatments are potential targets
against resistant forms of B-CLL (Kaufmann and Steensma, 2005;
Pleyer et al, 2009). The possibility that quercetin may ameliorate
efficacy of chemotherapy is strengthen by the safety of the
molecule administered through intravenous infusion. In fact, an
extensive phase I clinical trial established that at dose of
10.8mgkg
 1 body weight, no adverse effects were observed
(Ferry et al, 1996). The well-documented safety of quercetin
(Okamoto, 2005; Harwood et al, 2007), together with the
observation that quercetin does not induce apoptosis in human
peripheral mononuclear cells (Lugli et al, 2009; Russo GL, Russo M,
Spagnuolo C, data not shown), represents an important issue in
favour of its potential use in combination with other therapeutic
treatments, already approved and used in clinics.
The mechanism of action triggered by quercetin in CLL is still a
matter of study. As partially shown here and in agreement with
unpublished data from our laboratory on cell lines (Russo et al,i n
preparation), quercetin may exert its effect on both extrinsic and
intrinsic apoptotic pathways. We confirmed this possibility in
B-CLLs with the observation that quercetin triggers both
DR- (extrinsic pathway) and fludarabine (intrinsic pathway)-
induced cell death. The well-known antioxidant properties of the
molecule are independent from its apoptogenic activity when
associated with DRs or fludarabine. In fact, fluctuation of
intracellular reactive oxygen species in B-CLL cells does not
correlate with quercetin treatments and/or its cytotoxicity
(Supplementary Figure S2). A similar behaviour was reported in
leukaemic cell lines (Russo et al, 2003). We also explored other
mechanism(s) of action possibly triggered by quercetin. One
rationale hypothesis to explain the sensitising apoptotic effect of
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Figure 4 Cell viability assay in cells isolated from CLL patients and
treated with quercetin and fludarabine. Range of concentrations used is as
reported in Table 3. Values are presented as mean±s.e. (n¼29) and
significant differences were calculated using the two-tailed paired t-test.
Asterisk (*) indicates significant difference from quercetin (Po0.0005) and
fludarabine (Po0.0001).
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Figure 3 Caspase-9 activation in cells isolated from CLL patients. The
proteolytic activity of caspase-9 (nmol AFC per min per mg protein) was
measured in two selected samples isolated from CLL patients (CLL-55 and
CLL-56). Cells were treated as indicated in Table 2. Enzymatic activity was
reported as -fold increase compared with DMSO-treated cells after 12h
stimulation. Bar graphs represent the mean of two experiments (±s.e.).
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stimulate the expression of TRAIL receptor(s). In this context, it is
worthwhile to remember that pivotal works from Cohen’s group
showed that, in B-CLL, TRAIL-R1 is predominantly expressed over
TRAIL-R2, whereas no putative decoy receptors, TRAIL-R3 and
TRAIL-R4, are present on the surface of B-CLL cells (MacFarlane
et al, 2002, 2005). Unfortunately, we showed that quercetin does
not modify expression of TRAIL-R1 (Supplementary Figure S3).
Alternatively, considering the importance of Bcl-2 family member
in controlling apoptosis in B-CLL (Packham and Stevenson, 2005),
we tested the ability of quercetin to interfere with Bcl-2 proteins
regulation. Pro-apoptotic Bax and anti-apoptotic Bcl-xL cannot be
considered important, functional targets of quercetin in B-CLL as
their expression is extremely fluctuating in untreated B-CLL cells,
probably due to the heterogenicity of the disease (Supplementary
Figure S4A and B). In the case of pro-survival member Bcl-2, its
expression appears more constant in B-CLL isolated from patients,
but it is not influenced by quercetin treatment (Supplementary
Figure S4C). Currently, we are screening other possible direct or
indirect targets of quercetin that may be able to interfere with
apoptotic pathways in cellular models resembling B-CLL.
A novelty of this study is the demonstration that quercetin was
able to induce apoptosis in CLL samples in the absence of other
treatments (Figures 1 and 4; Table 2 and 3). B cells isolated from
patients were more sensitive to quercetin than cell lines of
leukaemic origin, which showed neither cytotoxicity, nor apoptosis
when treated with 50mM quercetin (Russo et al, 2007). In our view,
this represents an important issue that stimulates further studies in
the direction of therapeutic use of the molecule. Quercetin in CLLs
may function as a double-blade knife combining its intrinsic
apoptogenic activity with the ability to potentiate the effect of
other chemotherapeutic treatments.
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